Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Erythropoietin.

R G Kendall1

  • 1Abbott Diagnostics, Abbott House, Norden Road, Maidenhead, Berkshire, SL6 4XF, UK.

Clinical and Laboratory Haematology
|August 8, 2001
PubMed
Summary
This summary is machine-generated.

Maintaining red blood cell volume is crucial for oxygen delivery. Erythropoietin (EPO) regulates this balance, and its deficiency causes anemia, notably in kidney failure, where recombinant EPO (rHuEPO) therapy is effective.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Patients with pulmonary and cardiac disease show an elevated proportion of immature reticulocytes.

Clinical and laboratory haematology·2001
Same author

Red cell ferritin, a marker of iron deficiency in hemodialysis patients.

Renal failure·1998
Same author

Re-establishment of erythropoietin responsiveness in end-stage renal failure following renal transplantation.

Clinical nephrology·1995
Same author

Quantitative reticulocyte analysis may be of benefit in monitoring erythropoietin treatment in dialysis patients.

Artificial organs·1995
Same author

The effect of cytokines on the in-vitro erythropoietin bioassay.

Clinical and laboratory haematology·1994
Same author

Relationship between endogenous erythropoietin levels, reticulocyte count, and reticulocyte RNA distribution. A study of anemic patients with and without renal failure.

Annals of the New York Academy of Sciences·1994
Same journal

Cystic fibrosis presenting with haematological abnormalities.

Clinical and laboratory haematology·2006
Same journal

T-cell-rich B-cell lymphoma of the spleen presenting with severe hypersplenism.

Clinical and laboratory haematology·2006
Same journal

Spontaneous splenic haematoma in a multiple myeloma patient receiving pegfilgrastim support.

Clinical and laboratory haematology·2006
Same journal

Analysis of the CDR3 region of alpha/beta T-cell receptors (TCRs) and TCR BD gene double-stranded recombination signal sequence breaks end in peripheral blood mononuclear cells of T-lineage acute lymphoblastic leukemia.

Clinical and laboratory haematology·2006
Same journal

Characterization of several amino acid transports and glutamine metabolism in MOLT4 human T4 leukemia cells.

Clinical and laboratory haematology·2006
Same journal

Osteomylelitis and necrosis of the jaw in patients treated with bisphosphonates: a comparative study focused on multiple myeloma.

Clinical and laboratory haematology·2006
See all related articles

Area of Science:

  • Physiology
  • Hematology
  • Endocrinology

Background:

  • Red blood cell volume maintenance is vital for tissue oxygenation.
  • A delicate balance between red blood cell production (erythropoiesis) and loss maintains normal hematocrit.
  • Erythropoietin (EPO) is the key hormone regulating red blood cell production in response to oxygen levels.

Purpose of the Study:

  • To review the physiology and pathophysiology of erythropoietin (EPO).
  • To discuss the role of EPO in maintaining red blood cell homeostasis.
  • To highlight the clinical significance of EPO, particularly in anemia associated with renal failure.

Main Methods:

  • Review of existing literature on erythropoietin physiology and clinical applications.
  • Discussion of the homeostatic mechanisms involving EPO.

Related Experiment Videos

  • Analysis of the impact of recombinant human EPO (rHuEPO) therapy.

    • Main Results:

    • Erythropoietin (EPO) is the primary regulator linking tissue oxygen delivery to red blood cell production.
    • EPO deficiency leads to anemia, with end-stage renal failure being a common example.
    • Recombinant human EPO (rHuEPO) therapy has significantly improved the quality of life for patients with renal disease.

    Conclusions:

    • Erythropoietin (EPO) is an essential hormone for maintaining red blood cell homeostasis and oxygen transport.
    • Anemia due to EPO underproduction is a significant clinical issue, especially in chronic kidney disease.
    • The therapeutic use of recombinant EPO (rHuEPO) represents a major advancement in managing anemia.